1-19 of 19
Keywords: Alfuzosin
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1997) 32 (Suppl. 2): 45–47.
Published Online: 19 February 2019
... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Benign prostatic hyperplasia Alfuzosin...
Journal Articles
Subject Area:
Further Areas
European Urology (1996) 29 (1): 29–35.
Published Online: 11 August 2017
...B. Lukacs; P. Blondin; C. MacCarthy; B. Du Boys; P. Grippon; C. Lassale The safety profile of alfuzosin, a selective ai-adrenergic antagonist, was assessed in a total of 13,389 patients (mean age 66.9 ± 8.5 years) with symptomatic benign prostatic hypertrophy in two open, noncontrolled, multicentre...
Journal Articles
Subject Area:
Further Areas
European Urology (1993) 24 (Suppl. 1): 28–33.
Published Online: 11 August 2017
.... An observational, open-label, uncontrolled trial was designed to evaluate the impact of a 3-month therapy with alfuzosin (2.5 mg t.i.d.) on the quality of life of patients complaining of BPH-related symptoms for at least 6 months. Nine hundred and ninety patients were enrolled in 86 Italian centers of urology...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 39 (Suppl. 6): 7–12.
Published Online: 17 November 2004
... that α 1 blockers may improve the success rate of a TWOC. A placebo-controlled TWOC study of alfuzosin in 81 patients with AUR shows that a successful TWOC was achieved in 55% of alfuzosin-treated patients compared with 29% in the placebo group (p = 0.03). Long-term follow-up suggest that 32% (11/34; 22...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 39 (Suppl. 6): 19–26.
Published Online: 17 November 2004
...Ph.E.V. van Kerrebroeck Objectives: To assess the long-term efficacy and safety of alfuzosin 10 mg OD in patients with symptomatic BPH. Methods: Patients (>50 years) were randomised to alfuzosin 10 mg OD, alfuzosin 2.5. mg t.i.d. or placebo for 3 months. Open-label alfuzosin 10 mg OD...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 39 (Suppl. 6): 13–18.
Published Online: 17 November 2004
... transurethral resection of the prostate (TURP) and that emergency TURP for AUR is associated with greater morbidity than elective TURP. Risk factors for AUR include lower urinary tract symptoms (LUTS), depressed peak urinary flow rate, enlarged prostate, high postvoid residual (PVR) urine and old age. Alfuzosin...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 40 (Suppl. 3): 2–7.
Published Online: 19 December 2001
... to in the content or advertisements. BPH LUTS IPSS Data analysis IPHC Guidelines Alfuzosin Over the past 10 years, medical therapy has become the most commonly used treatment option for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), while at the same time...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 3): 52–63.
Published Online: 28 October 1999
... and pharmacological selectivity are not unequivocally reflected by experiments on so-called functional selectivity (in vivo experiments that differentiate urological and cardiovascular effects). Generally, α 1 -blockers that are efficacious in hypertension (doxazosin, terazosin, alfuzosin) are more likely to impair...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 1): 2–6.
Published Online: 22 June 1999
... target for the pharmacotherapeutic treatment of BPH. In this context, Alfuzosin was the first uroselective α 1 -adrenoceptor antagonist to be evaluated in the treatment of BPH and was subsequently marketed, initially in France, in 1987. This drug has since become the standard α 1 -adrenoceptor blocker...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1998) 34 (Suppl. 2): 18–28.
Published Online: 20 August 1998
... difference among the various α-blockers in terms of efficacy in treating LUTS. However, conventional quinazoline derivatives such as terazosin, doxazosin and alfuzosin, originally developed for hypertension, have inherent cardiovascular extension effects, which influence the well being and safety of patients...
Journal Articles
Subject Area:
Further Areas
European Urology (1998) 33 (Suppl. 2): 28–33.
Published Online: 11 March 1998
...B. Lukacs; J.C. Grange; C. McCarthy; D. Comet; B BPH Group in General Practice The objectives of this open-labeled study were to assess the clinical uroselectivity of alfuzosin in a long-term follow-up study in general practice. A total of 3,228 patients with clinical benign prostatic hyperplasia...
Journal Articles
Subject Area:
Further Areas
European Urology (1998) 33 (Suppl. 2): 2–6.
Published Online: 11 March 1998
... -subtypes (table  4 ). With specific reference to the α 1 -antagonists currently employed in the treatment of benign prostatic hyperplasia (BPH), alfuzosin shows similar high affinity for the 3 subtypes α 1a , α 1b and α 1d and tamsulosin shows a preferential affinity for the α 1a - and α 1d -subtypes...
Journal Articles
Subject Area:
Further Areas
European Urology (1998) 33 (Suppl. 2): 19–27.
Published Online: 11 March 1998
...Roger S. Kirby The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign...